Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
UCSF Helen Diller Family Comprehensive Cancer Center · Kanagawa Prefectural Hospital Organization · +28 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
992
total citations
- FWCI
- 295.09
- Percentile
- 100%
- References
- 33
Citations per year
Authors
214- RKRobin Kate Kelley
UCSF Helen Diller Family Comprehensive Cancer Center
- MUMakoto Ueno
Kanagawa Prefectural Hospital Organization, Kanagawa Cancer Center
- CYChanghoon Yoo
Ulsan College, Asan Medical Center, University of Ulsan
- RSRichard S. Finn
University of California, Los Angeles
- JFJunji Furuse
Kyorin University Hospital
Topics & keywords
Topics
Keywords
- Gemcitabine
- Medicine
- Internal medicine
- Pembrolizumab
- Placebo
- Oncology
- Cisplatin
- Clinical endpoint
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- SSanofi
- CCelgene
- BSBoston Scientific Corporation
- RPRegeneron Pharmaceuticals
- TPTaiho Pharmaceutical
- EExelixis
- CFCholangiocarcinoma Foundation
- LLLes Laboratories Pierre Fabre
- EPEA Pharma Co., Ltd.
- MMylan
- APAgios Pharmaceuticals
- BBeiGene
- IIncyte
- NNuCana
- RTRelay Therapeutics
- CTCompass Therapeutics
- MModerna
- EEisai
- APAstellas Pharma
- RSRussian Science Foundation
- TPTeijin Pharma
- SServier
- YHYakult Honsha
- OPOno Pharmaceutical
- IIpsen
- SMSirtex Medical
- AHAptitude Health
- GGenentech
- ESEMD Serono
- NPNovartis Pharma
- MSMerck Sharp and Dohme
- CPChugai Pharmaceutical
- ELEli Lilly Japan
- LOLoxo Oncology
- DSDaiichi Sankyo Europe